About the Activity

Learning Objectives

After completion of this educational activity, the participant should be able to

• explain the importance of resistance testing both before treatment initiation and after virologic failure


• differentiate initial ARV regimens in terms of the evolution of resistance among patients with virologic failure


• evaluate recent research findings related to the selection of viable first-line regimens for HIV-infected patients


• outline the advantages and disadvantages of NNRTI-based and PI-based initial therapy


• remove patients experiencing early virologic failure from nonsuppressive ARV regimens

Faculty

CO-CHAIR

Joseph J. Eron Jr, MD
Professor of Medicine
Division of Infectious Disease
UNC Chapel Hill School of Medicine
Chapel Hill, North Carolina

Graeme Moyle, MD, MBBS
Director of HIV Research Strategy
Chelsea and Westminster Hospital
London, United Kingdom

Statements and Disclaimers

AdvancMed is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AdvancMed is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The ACPE Universal Program Number for this activity is 379-000-08-006-H01-P.

Provider approved by the California Board of Registered Nursing, Provider Number 13429 for 2.5 contact hours.

*Credit Designation Statement
AdvancMed designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

AdvancMed provides this activity for 2.5 nursing contact hours.

AdvancMed provides this activity for 2.5 pharmacy contact hours (0.25 CEU).

Acknowledgment of Commercial Support
AdvancMed gratefully acknowledges Tibotec Therapeutics for the educational grant in support of this activity.

Off-label Statement/Unapproved Uses
In accordance with the Standards for Commercial Support and the Policy Compendium of the Accreditation Council for Continuing Medical Education, the audience is advised that one or more presentations in this continuing medical education activity may contain references to uses of drugs or devices that are off-label, investigational, or unapproved in the United States. This information is intended solely as continuing medical education and not to endorse off-label use. For US Food and Drug Administration (FDA)-approved prescribing information, please consult the product package insert.

Grievance Policy
Any grievance regarding this activity may be filed with AdvancMed’s Continuing Education (CE) Department. Please submit claims in writing either by mail at 1020 Monarch Street, Suite 200, Lexington, KY 40513 or by e-mail at info@advancmed.org. In compliance with our grievance policy, a representative of the AdvancMed CE Department will contact you within 2 business days of your submission.

Disclosure Statement
In accordance with the appropriate accrediting bodies, all planners, teachers, and authors with control over activity content are required to disclose to the provider any relevant financial relationships (those held by the planner or significant other, currently or within the last 12 months) with commercial interests. Accredited providers are then required to provide this information to participants before the start of an activity.

Disclaimer
None of the procedures, medications, devices, or other courses of diagnosis or treatment discussed or suggested in this activity should be used by clinicians without evaluating their patients’ conditions, considering possible contraindications, and reviewing generally accepted practices of medicine. Additionally, AdvancMed advises participants to confirm reimbursement eligibility before submitting a claim for off-label, unapproved uses, doses, or combinations of products.

Duplicate Credit Statement
This activity contains the same information as the Webinar series titled Preserving the Integrity of Future Treatment: ARV Regimens, Subsequent Choices, and the Cost of Resistance that was presented on February 12, 19, 21, 27, and 28, 2008. This activity also contains the same information as the archived Webinar titled Preserving the Integrity of Future Treatment: ARV Regimens, Subsequent Choices, and the Cost of Resistance that is currently available on demand at www.advancmed.org/286w. If you participated in any of these Webinars and received AMA PRA Category 1 Credit, nursing contact hours, or pharmacy contact hours, you may not receive credit for this activity. Please feel free to use the resource compendium as a resource.

Instructions for Participation
To receive verification of your participation, please follow these steps:

1. Register online.
2. Complete the Preactivity Questionnaire via an active Internet connection.
3. View the activity on the Web site.
4. Complete the Postactivity Evaluation via Internet connection.
5. Successfully complete all required steps for obtaining credit. If you have technical questions, please contact info@advancmed.org.

Minimum System Requirements
For Windows Users:

1. Microsoft Windows XP Professional or Home Edition with Service Pack 2 or Windows Vista
2. Internet Explorer 6 or 7 or Netscape Navigator 8.1 or Mozilla Firefox 1.5.04
   

For Macintosh Users:

1. Mac OS X v10.4
2. Safari 2.0 or Mozilla Firefox 1.5.03
   

Additional requirements for all users:

1. Adobe Flash Player 8 or 9
2. Broadband (DSL, Cable, LAN) Internet connection
3. Cookies enabled in your Web browser
4. A printer for printing your certificate